Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique could improve heart attack treatment outcomes

NCT ID NCT06227754

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to guide stent placement during a heart attack: standard angiography (X-ray) versus a more detailed imaging method called optical coherence tomography (OCT). The goal is to see if OCT leads to fewer future heart problems, like repeat blockages or heart-related death. The trial will enroll 1,500 adults with a specific type of heart attack (STEMI) who are treated within 12 hours of symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optical coherence tomography (OCT) imaging guidance
What this could lead to
If successful, this could show that using OCT during heart attack treatment reduces the risk of future heart problems or the need for repeat procedures.
What could go wrong
This is a large trial but still early in testing a procedure, not a drug. The benefit may be small or not apply to all patients. Risks include those of the standard procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be at least 19 years of age * Acute ST-segment elevation myocardial infarction (STEMI) \*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1 * Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients * Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: * Target lesions not amenable for PCI by operators' decision * Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion) * Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance) * Cardiogenic shock (Killip class IV) at presentation * Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus * Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) * Pregnancy or breast feeding * Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment) * Unwillingness or inability to comply with the procedures described in this protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction ST elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University

    RECRUITING

    Gwangju, Gwangju, 61469, South Korea

  • Chung-Ang University Hospital

    RECRUITING

    Seoul, Seoul, 06973, South Korea

  • Daegu Catholic University Medical Center

    RECRUITING

    Daegu, Daegu, 42472, South Korea

  • Ewha Womans University Mokdong Hospital

    RECRUITING

    Seoul, Seoul, 07985, South Korea

  • Ewha Womans University Seoul Hospital

    RECRUITING

    Seoul, Seoul, 07804, South Korea

  • Gyeongsang National University Hospital

    RECRUITING

    Jinju, Jinju, 52727, South Korea

  • International St. Mary's Hospital

    RECRUITING

    Incheon, Incheon, 22711, South Korea

  • Jeju National University Hospital

    RECRUITING

    Jeju City, Jeju-do, 63241, South Korea

  • Jeonbuk National University Hospital

    RECRUITING

    Jeonju, Jeonju, 54907, South Korea

  • Korea University Guro Hospital

    RECRUITING

    Seoul, Seoul, 08308, South Korea

  • Kyung Hee University Hospital

    RECRUITING

    Seoul, Seoul, 02447, South Korea

  • Kyungpook National University Hospital

    RECRUITING

    Daegu, Daegu, 41944, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • St. Carollo Hospital

    RECRUITING

    Suncheon, Suncheon, 57931, South Korea

  • Uijeongbu St Mary's Hospital

    RECRUITING

    Uijeongbu-si, Uijeongbu, 11765, South Korea

  • Ulsan University Hospital

    RECRUITING

    Ulsan, Ulsan, 44033, South Korea

  • Wonkwang University Hospital

    RECRUITING

    Iksan, Iksan, 54538, South Korea

  • Yeungnam University Medical Center

    RECRUITING

    Daegu, Daegu, 42415, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.